850462-64-5

Usage

Uses

Used in Organic Synthesis:
5-Fluoro-2-Methyl-3-nitrobenzoic acid is used as a building block in organic synthesis for the creation of more complex organic molecules. Its presence of a fluorine atom, methyl group, and nitro group allows for versatile chemical reactions, making it a valuable component in the synthesis of various organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-Fluoro-2-Methyl-3-nitrobenzoic acid is utilized as a reagent in chemical reactions. Its unique structure contributes to the development of new pharmaceutical drugs, aiding in the advancement of medicinal chemistry by providing a platform for the synthesis of potential therapeutic agents.
Used in Drug Production:
5-Fluoro-2-Methyl-3-nitrobenzoic acid is employed in the production of pharmaceutical drugs. Its chemical properties make it a suitable precursor for the synthesis of active pharmaceutical ingredients, contributing to the development of new medications for various medical conditions.
It is important to handle and store 5-Fluoro-2-Methyl-3-nitrobenzoic acid with care due to its potential hazards, ensuring safety in laboratories and industrial settings where it is used.

InChI:InChI=1/C8H6FNO4/c1-4-6(8(11)12)2-5(9)3-7(4)10(13)14/h2-3H,1H3,(H,11,12)

Upstream product

• 33184-16-6 5-fluoro-2-methylbenzoic acid 
• 13194-67-7 4-fluoro-2-iodotoluene 
• 1422-53-3 2-bromo-4-fluorotoluene 
• 452-73-3 2-chloro-4-fluorotoluene 

Downstream Products

• 246877-30-5 5-fluoro-2-methyl-3-nitrobenzoic acid benzyl ester 
• 246877-31-6 3-amino-5-fluoro-2-methylbenzoic acid 
• 246877-29-2 5-fluoro-3-hydroxy-2-methylbenzoic acid 
• 697739-03-0 5-fluoro-2-methyl-3-nitrobenzoic acid methyl ester 
• 1082040-43-4 6-fluoro-1H-indole-4-carboxylic acid methyl ester 
• 446-10-6 2-nitro-4-fluorotoluene 

Relevant academic research and scientific papers

METHOD FOR PREPARATION OF 5-FLUORO-2-METHYL-3-NITROBENZOIC ACID AND ITS METHYL ESTER

The invention discloses a method for preparation of 5-fluoro-2-methyl-3-nitrobenzoic acid and its methyl ester by conversion of 5-fluoro-2-methylbenzoic acid with fuming nitric acid and oleum and subsequent conversion with methanol.

ETHER COMPOUNDS AND USES THEREOF

The present invention provides compounds that modulate protein function, to restore protein homeostasis and/or cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions of these compounds are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions are also provided.

Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation

Estrogens are the major female sex steroid hormones, estradiol (E2) being the most potent form in humans. Disturbing the balance between E2 and its weakly active oxidized form estrone (E1) leads to diverse types of estrogen-dependent diseases such as endometriosis or osteoporosis. 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyzes the biosynthesis of E2 by reduction of E1 while the type 2 enzyme catalyzes the reverse reaction. Thus, 17β-HSD1 and 17β-HSD2 are attractive targets for treatment of estrogen-dependent diseases. Recently, we reported the first proof-of-principle study of a 17β-HSD2 inhibitor in a bone fracture mouse model, using subcutaneous administration. In the present study, our aim was to improve the in vitro ADME profile of the most potent 17β-HSD1 and 17β-HSD2 inhibitors described so far. The optimized compounds show strong and selective inhibition of both the human enzymes and their murine orthologs. In addition, they display good metabolic stability in human liver microsomes (S9 fraction), low in vitro cytotoxicity as well as better aqueous solubility and physicochemical properties compared to the lead compounds. These achievements make the compounds eligible for testing in preclinical in vivo animal model studies on the effects of inhibition of 17β-HSD1 and 17β-HSD2.

HISTONE METHYLTRANSFERASE EZH2 INHIBITOR, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF

The invention relates to a histone methyltransferase EZH2 inhibitor, a preparation method and pharmaceutical use thereof. In particular, the invention relates to a compound represented by the general formula (I), a preparation method thereof, a pharmaceut

Preparation method for 2-methyl-5-fluorobenzoic acid

The invention discloses a preparation method for 2-methyl-5-fluorobenzoic acid. The method comprises the steps of reacting 2-X-4-fluorotoluene with magnesium chips to form a Grignard reagent, and converting the obtained Grignard reagent to obtain the 2-methyl-5-fluorobenzoic acid, wherein X is selected from chloro, bromo or iodo.

Novel compounds

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

Isoindoline derivative and intermediate, preparation method, pharmaceutical composition and application thereof

The invention discloses an isoindoline derivative, and an intermediate, a preparation method, a pharmaceutical composition and application thereof. The isoindoline derivative of the invention and the pharmaceutical composition thereof can adjust productio

Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2

Provided herein are non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 and type 2 (17β-HSD1 and 17β-HSD2) inhibitors, their production and use, especially for the treatment and for prophylaxis of hormone-related diseases.

NOVEL COMPOUNDS

The preseent invention relates to novel retinoid-related orphan receptor gamma(RORγ)modulators and their use in the treatment ofdiseases mediated by RORγ.

NOVEL COMPOUNDS

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.